This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Statistics and Research Methods  • Humanities  • Medicine and the Media  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

A Call for Papers

Gianna Zuccotti, MD, MPH; Jeanette M. Smith, MD

JAMA. 2007;298(21):2545.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Time provides a metric for judging the long-term success of battles fought and won. More than a decade ago, the advent of protease inhibitors for human immunodeficiency virus (HIV) disease was hailed as having great promise,¹ which has been borne out by experience. Hope for medications that inhibit HIV entry was realized with the recent approval of a drug that blocks the CCR5 coreceptor² and a fusion inhibitor in 2003.³ An integrase inhibitor affecting an enzyme needed for HIV replication has now been approved.⁴ Each represents the first agent in new classes of HIV drugs.

These notable advances in treatment options are occurring in parallel with efforts to improve access to treatment⁵ and strengthen prevention initiatives.^6-7 However, the summary statistics of the AIDS epidemic remain sobering: there were an estimated 39.5 million individuals living with HIV worldwide in 2006.⁸ Despite immense effort, . . . [Full Text of this Article]

Author Affiliations: Dr Zuccotti (gianna.zuccotti@jama-archives.org) and Dr Smith (jeanette.smith@jama-archives.org) are Contributing Editors, JAMA, Chicago, Illinois.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?